Prof Research published a new market report on the acromegaly treatment market. It presents the largest 5 manufacturers in the acromegaly treatment drugs market. The report is a professional and in-depth study on the current state of the global acromegaly treatment market. The report provides key statistics on the market of acromegaly treatment. It is a valuable source of guidance and direction for companies and individuals interested in the acromegaly treatment industry.

The global acromegaly treatment market was valued to be 4,923.7 million USD in 2021. The acromegaly treatment production value is anticipated to have grown with a CAGR of 3.84% in the coming years to reach 6,172.6 million USD in 2027.

Novartis is the largest manufacturer of acromegaly treatment in the world, it has a market share of 12.3% in value. It operates two divisions: Innovative Medicines and Sandoz. Medicines division, made up of two business units – Novartis Pharmaceuticals and Novartis Oncology, commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines.

Ipsen is the second-largest manufacturer of acromegaly treatment in the world, it has a market share of 8.1% in value. The Company operates globally through two segments: Specialty Care and Consumer Healthcare.

Pfizer is the third-largest manufacturer of acromegaly treatment in the world, it has a market share of 5.6% in value. Its global portfolio includes medicines and vaccines.

Recordati is the fourth largest manufacturer of acromegaly treatment in the world, it has a market share of 0.9% in value. Recordati focuses its research and development activities mainly on the area of rare diseases.